Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 20/20 | 1.00 |
| ▸ | EPAS1 | Q99814 | 20/20 | 1.00 |
| ▸ | EP300 | Q09472 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2563518 | 1.00 | HIF1A (1.00) | HIF1AEPAS1EP300 | |
| SCHEMBL2558097 | 0.90 | HIF1A (1.00) | HIF1AEPAS1EP300 | |
| SCHEMBL2562218 | 0.89 | HIF1A (1.00) | HIF1AEPAS1EP300 | |
| SCHEMBL14071518 | 0.86 | HIF1A (0.76) | HIF1AEPAS1EP300 | |
| SCHEMBL2564166 | 0.85 | HIF1A (1.00) | HIF1AEPAS1EP300 | |
| SCHEMBL2565162 | 0.84 | HIF1A (1.00) | HIF1AEPAS1EP300 | |
| SCHEMBL2562044 | 0.84 | HIF1A (1.00) | HIF1AEPAS1EP300 | |
| SCHEMBL2560066 | 0.83 | HIF1A (1.00) | HIF1AEPAS1EP300 | |
| SCHEMBL2562559 | 0.82 | HIF1A (1.00) | HIF1AEPAS1EP300 | |
| SCHEMBL14916669 | 0.81 | HIF1A (1.00) | HIF1AEPAS1EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023056451-A1 | COMPOSITIONS AND METHODS FOR ASSAYING FOR AND GENOTYPING GENETIC VARIATIONS | MAMMOTH BIOSCIENCES, INC. (US) | 2023-04-06 | — | — | WO | claimed |
| US-20230073777-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-03-09 | — | — | US | claimed |
| US-20260078132-A1 | SOLID FORMS OF AN INHIBITOR OF HIF AND METHODS OF USING SAME | ONCOSPHERIX INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20250325678-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2025-10-23 | — | — | US | disclosed |
| EP-4587442-A1 | SOLID FORMS OF AN INHIBITOR OF HIF AND METHODS OF USING SAME | ONCOSPHERIX INC. (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-116507333-B | Cyclic AMP response element binding protein (CBP) and/or 300KDA adenovirus E1A binding protein (P300) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20250115961-A1 | DIAGNOSIS AND TREATMENT OF MÉNIÈRE'S DISEASE (MD) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-04-10 | — | — | US | disclosed |
| CN-119707811-A | Indenoquinoline fluorescent probe molecule based on sulfite ions and synthesis method and application thereof | 广东轻工职业技术大学 | 2025-03-28 | — | — | CN | disclosed |
| CN-119330963-A | Cyclic AMP response element binding protein (CBP) and/or 300KDA adenovirus E1A binding protein (P300) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2025-01-21 | — | — | CN | disclosed |
| US-20240279660-A1 | Methods and Compositions for Managing Vascular Conditions Using miR-483 Mimics and HIF1alpha Pathway Inhibitors | UNIV EMORY (US) | 2024-08-22 | — | — | US | disclosed |
| CN-118451103-A | Compositions and methods for treating long QT syndrome | 伯尔尼大学 | 2024-08-06 | — | — | CN | disclosed |
| CN-116507333-A | Cyclic AMP response element binding protein (CBP) and/or 300KDA adenovirus E1A binding protein (P300) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2023141498-A2 | DIAGNOSIS AND TREATMENT OF MÉNIÈRE'S DISEASE (MD) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-27 | — | — | WO | disclosed |
| CN-107846898-B | Diphenyl methanol derivatives for management of hypoxia inducible factor related disorders | 佐治亚州立大学研究基金会 | 2023-07-14 | — | — | CN | disclosed |
| CN-114547064-B | Product searching method, system, computer equipment and readable storage medium | 广州万物集工业互联网科技有限公司 | 2023-07-07 | — | — | CN | disclosed |
| WO-2023056451-A1 | COMPOSITIONS AND METHODS FOR ASSAYING FOR AND GENOTYPING GENETIC VARIATIONS | MAMMOTH BIOSCIENCES, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20230073777-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-03-09 | — | — | US | disclosed |
| CN-114547064-A | Product searching method, system, computer equipment and readable storage medium | 广州盖盟达工业品有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220090079-A1 | Methods and Compositions for Managing Vascular Conditions Using miR-483 Mimics and HIF1alpha Pathway Inhibitors | UNIV EMORY (US) | 2022-03-24 | — | — | US | disclosed |
| WO-2022042707-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230073777-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CREBBP, EP300, CREB1 | HIF1A 2894/4885EPAS1 393/4885EP300 2/4885 |
| US-20250325678-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CREBBP, EP300, CREB1 | HIF1A 2894/4885EPAS1 393/4885EP300 2/4885 |
| US-20260078132-A1 | SOLID FORMS OF AN INHIBITOR OF HIF AND METHODS OF USING SAME | VHL, HIF1AN, HIF1A | HIF1A 3/4885EPAS1 83/4885EP300 1286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.